[Past Event] How Investment in Open Innovation Can Lead Us to More Accessible Health Care
The public health emergency around COVID-19 has shown that substantial stakeholder (both government and private) funding to de-risk clinical development, manufacturing development, drug supply security and commercialization can incentivize the industry to cooperatively act to develop vaccines, therapies, diagnostics and treatment regimens more quickly than ever before. These stakeholder incentives for collaboration and open innovation can replace traditional intellectual property rewards for biopharmaceutical R&D. The industry already adopted elements of these factors in CivicaRx, Just Biotherapeutics (no longer independent), Audacity Therapeutics, Medicines4Kids (M4K) and others. Join Worth, Kathleen Entwistle, Paul Fehlner, Barbara Handelin and other special guests as we explore how open innovation in medicine will change the future of healthcare.
Featuring: Kathleen Entwistle, Private Wealth Advisor, Morgan Stanley Private Wealth Management, Paul Fehlner, Co-founder & President/CEO, reVision Therapeutics, Inc. and Barbara Handelin, PHD, Co-Founder & CEO, Audacity Therapeutics, PBC
Moderated by: Juliet Scott-Croxford, CEO, Worth
By registering for this event I agree I want to receive news, updates and invitations from Worth using the information provided on this form. I consent to Worth, its affiliates and service providers processing my personal data for these purposes.
Watch Past Webinars:
- Thursday, January 7, 12 p.m. ET/ 9 a.m. PT
A leader in private wealth management for successful families, women and business owners.
Kathy joined UBS in 2007 and subsequently formed Entwistle Partners, creating a team of professionals dedicated to providing multigenerational wealth advice to affluent families, C-suite executives and founders.
With her nearly 30-year career defined by many leadership roles, Kathy has been recognized with multiple awards and designations for her achievements—from Forbes as a Top 200 female financial advisor in the country to three consecutive Barron’s nominations to their “Top Women Financial Advisors” list. Kathy attributes her success to her dedicated team who help her deliver on strong personal relationships, thoughtful advice and a high level of service.
Officer in Corporate Trust Department, Manufacturers Hanover Trust
Vice President and Wealth Advisor, Morgan Stanley
Certified Financial Planner, (CFP®)
Certified Divorce Financial Analyst (CDFA®)
Forbes “Top Women Wealth Advisor,” 2018, 2019
Forbes “Best-in-State Wealth Advisor,” New Jersey, 2017, 2018, 2019, 2020
Forbes “Top 200 Women Advisors,” 2017, 2018
M.B.A., Fordham University
Kathy serves on the Board of Directors for: The Ridgewood Public Library Foundation, The Family Support Organization of Bergen County, St, Joseph’s School for the Blind, Christian Health Care Center Foundation, and Ridgewood A.M. Rotary.
She is an active member of the Commerce and Industry Association of New Jersey and Women United in Philanthropy.
In her free time, she enjoys golfing, spending time with family and relaxing at the beach.
Paul Fehlner is a co-founder and President/CEO of reVision Therapeutics, Inc., which was created to advance low price innovative medicines through open innovation principles. Concurrently, he is Chief LegalOfficer at Axcella Health, a clinical stage company in Cambridge, Massachusetts and a Principal of Life Sciences Innovation LLC, a consulting company that advises on products and technologies and provides BD&L support in life sciences. Previously, Dr. Fehlner was Head of Intellectual Property for Novartis Pharma in Basel, Switzerland, leading a team of over 120 colleagues in 5 countries to obtain, maintain, and enforce IP rights for the company in collaboration with global and local stakeholders. Dr. Fehlner joined Novartis in 2008 from the international law firm Baker Botts, where he led the firm’s life sciences IP practice. He was an associate and partner at Darby & Darby, Biotechnology Counsel for Rhône-Poulenc Rorer, an associateat Klauber & Jackson, and began his career in 1990 at Pennie & Edmonds. Hehas a JD from Fordham, a PhD from Rockefeller University (Lois P Markey Fellow), and a BS from Haverford College (high honors; Phi Beta Kappa).
Dr. Handelin is a veteran entrepreneur and molecular medical geneticist who has pioneered the responsible application of genetics to clinical medicine over a 20-year career. In 1987 Dr. Handelin established one of the first commercial DNA testing laboratories at Integrated Genetics (now Genzyme Genetics). After co-founding a gene therapy company (Genovo), Dr. Handelin began her own consulting practice, Handelin Associates. She delivered consulting services to venture capital investors, start-ups, biomedical universities, biotechnology, diagnostics, genomics, pharmacogenomics and bioinformatics companies. She founded a biosimulation company, Kenna Technologies, where she has served as CEO until its acquisition by DNA Print Genomics. At DNAG she led the development of new pharmacogenetics diagnostic tests as well as bringing DNA identity technology to intelligence and forensic criminal investigations. In 2014 she cofounded the nonprofit organization, BioPontis Alliance for Rare Diseases, dedicated to a nontraditional model for drug discovery in rare, orphan diseases. Today she is founding Audacity Therapeutics, PBC, a new business model in the biopharmaceutical industry, bringing affordable medicines for unmet medical needs, utilizing the revisited, reconsidered, repurposed and reformulation wealth of existing drugs. She also serves the research management needs of rare disease patient organizations through NovoKen, LLC. Dr. Handelin served on the boards of several genomics companies (e.g. EXACT Sciences and RedPath Integrated Pathology). She served 10 years as a board member of Public Responsibility in Medicine and Research (PRIM&R) as well as on a variety of federal committees and advisory panels on ethics in genetic testing, including the Secretary’s Advisory Panel on Genetics, Health and Society.
Juliet currently serves as CEO for media brand Worth, responsible for leading its transformation from a print magazine to a content platform that focuses on ‘Worth beyond Wealth’ and inspires and informs an affluent, influential and successful community of individuals to be their best selves.
Juliet began her career as a management consultant, learning to code at IBM Business Consulting Services, before focusing on business strategy and organizational change, working with clients to solve complex business problems across a variety of sectors through the use of technology.
Her experience in this area took her to a role at Boxwood (now KPMG) where she worked as a senior consultant in strategy and business change, with a focus on the media and technology sector. After working as a consultant with Guardian News & Media on its print to digital strategy, in 2012 she was confirmed in a permanent role to lead strategy and operations for the Guardian Media Group’s commercial division based in London.
Juliet joined the Guardian’s executive committee in 2015 and, as chief delivery officer; was responsible for the strategic implementation of the global three year turnaround plan and subsequent transformation and growth for the Guardian’s US operation, relocating to New York in 2016.
She lives in Brooklyn with her husband and son, is a keen runner, yogi, and skier.